Aller au contenu principal
Profil bibliographique

Pruthali Kulkarni

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
9Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchMultiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies

Les publications récentes

2026 conference-abstract OpenAlex

Clinicopathologic differences in early- vs. late-onset pancreatic cancer: A retrospective cohort study.

Priyanka Reddy, Derek Friesen, Maryana Stryelkina, Pruthali Kulkarni et autres

e16397 Background: Pancreatic cancer diagnosed in patients younger than 50 years has become increasingly common over the past two decades. In the United States, early-onset pancreatic cancer (EOPC) increased from approximately 1.1 to 1.4 per 100,000 between 2013 and 2022, with similar …

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2022 article OpenAlex

Pembrolizumab-Induced Immune-Mediated Glossitis

Alwin Alias, James A.M. Hall, Pruthali Kulkarni, Alan C Gowan

Pembrolizumab (Keytruda), an anti-PD-1 antibody used in the treatment of several different malignancies has been identified to cause adverse effects pertaining to multiple body systems which include respiratory, gastrointestinal, dermatologic, and endocrine manifestations known as immune-related adverse events (IRAEs). Skin manifestations have …

us (code pays fourni par la source)

5 citations Cureus
Accès ouvert 2021 article OpenAlex

Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy

Pruthali Kulkarni, James A.M. Hall, Liping Wang, Sherronda Henderson

Anaplastic thyroid cancer is an extremely aggressive disease, which at diagnosis is presumed to be stage IV, has a one-year survival of <10%, and at present has no definitive therapy. The combination of dabrafenib/trametinib has recently been investigated in cancers with BRAF …

us (code pays fourni par la source)

4 citations Cureus
2021 conference-abstract OpenAlex

Correlation of Agent Orange exposure, cytogenetics, and clinical outcomes in multiple myeloma and MGUS.

Pruthali Kulkarni, Laurel Copeland, James A. Hall, Jyothi Dodlapati

e20008 Background: Multiple myeloma (MM) accounts for 1-2% of cancers worldwide. MM and monoclonal gammopathy of unknown significance (MGUS) are associated with Agent Orange exposure (AO) in Vietnam war veterans. Studies show poor outcomes in AO-exposed patients developing MM. No study has …

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology
Accès ouvert 2021 article OpenAlex

Relapsing Multiple Myeloma Presenting as Cardiac Tamponade and Obstructive Uropathy

Bright E Izekor, Pruthali Kulkarni, Priscilla R. Powell, James A. Hall et autres

Cardiac tamponade is a rare manifestation of relapsing extramedullary multiple myeloma and portends poor prognosis. No cases of cardiac tamponade with co-occurring renal obstruction from plasmacytoma have been reported in the literature, making this case a unique presentation of relapsing multiple myeloma. …

us (code pays fourni par la source)

0 citations Cureus

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.